NCT03467763View on ClinicalTrials.gov

Trial of an Intervention to Improve Metformin Persistence and Adherence

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

February 1, 2020

Study Completion Date

August 1, 2020

Conditions
Metformin Adverse ReactionTolerance
Interventions
DRUG

Metformin Extended Release Oral Tablet

Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.

DRUG

Placebo oral capsule

Placebo capsule

Trial Locations (1)

10065

Weill Cornell Medical College, New York

All Listed Sponsors
collaborator

Agency for Healthcare Research and Quality (AHRQ)

FED

lead

Weill Medical College of Cornell University

OTHER

NCT03467763 - Trial of an Intervention to Improve Metformin Persistence and Adherence | Biotech Hunter | Biotech Hunter